ArticleFrontiers in oncology2026
Global burden of thyroid cancer in males: a comprehensive analysis of incidence, mortality, and risk factors from 1990 to 2040.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid cancer incidence has increased globally, with notable gender disparities in epidemiological patterns and outcomes. This study examines the global burden of thyroid cancer in males from 1990 to 2021 and projects trends to 2040. Methods: Using data from the Global Burden of Disease Study 2021, the author analyzed age-standardized incidence, prevalence, deaths, and disability-adjusted life years (DALYs) for thyroid cancer in males across 204 countries and territories. Bayesian meta-regression and ensemble modeling techniques were employed to estimate trends and generate projections. Results: Global male thyroid cancer incidence increased from 1.2 to 2.0 per 100,000 (EAPC: 1.78%, 95% CI: 1.64-1.92) between 1990 and 2021, while mortality remained stable (0.4 to 0.5 per 100,000; EAPC: 0.41%, 95% CI: 0.35-0.46). Significant geographical variations were observed, with high-SDI regions showing the highest incidence rates but the most stable mortality patterns. Projections to 2040 indicate continued incidence increases (2.16 per 100,000) with stable mortality (0.45 per 100,000), though uncertainty intervals widen substantially in later years. Conclusion: The diverging trends between rising incidence and stable mortality in male thyroid cancer suggest substantial, particularly in developing regions. Gender differences in disease characteristics and outcomes highlight the need for sex-specific clinical approaches. These findings emphasize the importance of implementing evidence-based diagnostic practices to minimize overdiagnosis while ensuring appropriate care for advanced cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.